Novartis Offers Dividend Investors Strong Yield and Profitability
Novartis passed a dividend-focused screen with a 3.72% yield and a high profitability rating. It has paid dividends for at least a decade without cuts in the past five years and has modest dividend growth, but its payout ratio is elevated. The article also notes a moderate health score and cautions that the payout may not be sustainable on its own.
Novartis’s ADR cleared a dividend screen requiring at least a 7 dividend rating, 5 profitability, 5 health, plus minimum liquidity and price thresholds. Its scores were 7, 9, and 5, with an overall fundamental rating of 6. The 3.72% yield exceeds the S&P 500’s 2.02% average and beats 92.71% of industry peers.
The company has paid dividends for at least ten years, avoided cuts over five years, and grown them 5.44% annually. However, the 71.08% payout ratio is elevated. Strong margins, returns, and five years of positive operating cash flow and profits support the income case, though the health score carries caveats.
This story may matter to income-focused investors, including retirees and savers, who could weigh Novartis’s yield against its elevated payout ratio. If dividends remain supported by profits, shareholders may receive steady income; if payout pressure grows, any reduction could affect household budgets. Broader market watchers may see it as a reminder that high yield and profitability do not eliminate sustainability risk.